Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result Spotlight
Bladder and urothelial cancer
EV-103: Enfortumab vedotin (Nectin-4 ADC) + pembrolizumab (PD-1) sustains 41.5% 5-year survival in 1L cisplatin-ineligible la/mUC
Enfortumab vedotin is a Nectin-4–directed antibody–drug conjugate delivering MMAE, combined here with pembrolizumab (anti–PD-1) as first-line therapy in EV-103 dose escalation/cohort A (Phase Ib/II; NCT03288545) for…
NCT03288545 - New trial Spotlight
Bladder and urothelial cancer
Phase 3 EV-309 tests enfortumab vedotin Nectin-4 ADC + pembrolizumab PD-1 inhibitor
This Phase 3, open-label, randomized, multicenter study (EV-309) evaluates bladder-preserving enfortumab vedotin plus pembrolizumab versus concurrent chemoradiotherapy (cCRT) in adults with non-metastatic…
NCT07566156 Registrational - New trial Spotlight
Prostate cancer
Phase 3 BNT324 (DB-1311) B7-H3–targeted topoisomerase I–payload ADC vs docetaxel in mCRPC.
This randomized, open-label Phase 3 BioNTech SE study compares BNT324 (also known as DB-1311) with docetaxel plus prednisone/prednisolone in men with progressive metastatic castration-resistant prostate cancer who…
NCT07365995 Registrational - New trial
Prostate cancer
Phase 1b xaluritamig (AMG 509) STEAP1×CD3 bispecific T‑cell engager in mCRPC.
This Phase 1b, open-label study from Amgen evaluates the safety (primary) and early activity of xaluritamig at the proposed regimen in adults with metastatic castration-resistant prostate cancer who have progressed…
NCT07493512 Exploratory - New trial
Prostate cancer
Pilot randomized study uses bicalutamide androgen-receptor inhibitor to modulate PSMA imaging signal
Washington University School of Medicine is running this randomized, open-label pilot study to test whether a short course of bicalutamide (a nonsteroidal androgen receptor inhibitor) alters PSMA expression enough to…
NCT07593079 Exploratory - New trial
Breast cancer
Early Phase 1 mitazalimab CD40 agonist +/− nivolumab PD-1 inhibitor intratumoral in resectable breast cancer
This early Phase 1 “window-of-opportunity” study tests whether a single intratumoral injection of mitazalimab (a CD40 agonistic monoclonal antibody that activates antigen-presenting cells to enhance T-cell priming)…
NCT07319195 Exploratory - New trial
Breast cancer
Phase 2 bupropion XL norepinephrine–dopamine reuptake inhibitor to improve AI tolerance (HSDD)
University of Illinois at Chicago is running this Phase 2 supportive-care study in women with resected, early-stage hormone receptor–positive breast cancer taking adjuvant aromatase inhibitor (AI) therapy who develop…
NCT07596212 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1/2 AdaptNK adaptive CMV-induced NK-cell immunotherapy (KIR–HLA mismatch bridge-to-transplant) in R/R AML.
This Phase 1/2, open-label, multi-institution study from Masonic Cancer Center (University of Minnesota) tests an allogeneic KIR–HLA–mismatched natural killer (NK) cell infusion, “AdaptNK,” followed by a short course…
NCT07591649 Exploratory - New trial
Uterine (endometrial) cancer
Phase 2 pembrolizumab PD-1 inhibitor + lenvatinib multi-kinase (VEGFR/FGFR) inhibitor in pMMR endometrial cancer.
This Phase 2, open-label, single-arm study at the University of Miami evaluates pembrolizumab (Merck/MSD; PD-1–blocking monoclonal antibody that restores T-cell anti-tumor activity) combined with lenvatinib (Eisai;…
NCT07594015 Exploratory - New trial
Brain and CNS tumors
Phase 1/2 MT-125 non-muscle myosin II (IIA/IIB) inhibitor with chemoradiation in GBM
Myosin Therapeutics’ Phase 1/2 NOVA-GBM study tests MT-125, a CNS-penetrant small-molecule inhibitor of non-muscle myosin II paralogs IIA and IIB, given alongside standard chemoradiation for newly diagnosed…
NCT07604285 Exploratory - New trial Spotlight
Ovarian cancer
Phase 1 XmAb541 CLDN6×CD3 T‑cell–engaging bispecific + XmAb808 B7‑H3×CD28 costimulatory bispecific
Xencor’s open-label Phase 1 study (sequential assignment) dose-escalates then dose-expands XmAb541 with XmAb808 to define safety, dose-limiting toxicities, PK, and early antitumor activity (RECIST 1.1) in CLDN6+…
NCT07593092 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 2/3 EIK1001 TLR7/8 agonist + pembrolizumab chemo in 1L stage 4 NSCLC
This global, multicenter, randomized, double-blind, placebo-controlled adaptive Phase 2/3 trial (TeLuRide-008) tests whether adding Eikon Therapeutics’ EIK1001—an IV Toll-like receptor 7/8 (TLR7/8) innate immune…
NCT07365319 Exploratory - New trial
Non-small cell lung cancer
Phase 2 nivolumab PD‑1 inhibitor + hypofractionated ablative RT vs docetaxel chemo
University of Chicago is running a randomized Phase 2 study testing whether adding hypofractionated ablative external-beam radiotherapy (EBRT) to continued immune checkpoint inhibition can improve outcomes in…
NCT07603856 Exploratory - New trial
Non-small cell lung cancer
Phase 2 ivonescimab PD-1×VEGF bispecific antibody consolidation after SBRT in early NSCLC
Memorial Sloan Kettering Cancer Center is running I-PRECISE, a Phase 2 study asking whether adding ivonescimab after definitive stereotactic body radiotherapy (SBRT)—delivered with either photon or proton…
NCT07594522 Exploratory - New trial Spotlight
Small cell lung cancer
Phase 1b tarlatamab DLL3×CD3 T‑cell engager + ZL‑1310 DLL3 Topo‑I ADC ± durvalumab
Amgen’s open-label Phase 1b study tests whether dual DLL3 targeting can deepen responses in relapsed/recurrent small cell lung cancer: tarlatamab (a DLL3×CD3 bispecific antibody that redirects T cells to…
NCT07531095 Exploratory - New trial
Chronic myeloid leukemia
Phase 1/2 asciminib STAMP BCR-ABL1 inhibitor with FLAG-Ida + venetoclax BCL-2 inhibitor
MD Anderson is running this Phase 1b/2 study to define safety (Phase 1b) and estimate efficacy (Phase 2) of adding asciminib (Novartis; a STAMP inhibitor that targets the ABL myristoyl pocket on BCR-ABL1) to…
NCT07604233 Exploratory - New trial
Multiple myeloma
Phase 1b/2 isatuximab + iberdomide cereblon E3-ligase modulator combo in NDMM
Dana-Farber Cancer Institute is running this Phase 1b/2, open-label study testing a four-drug induction regimen—isatuximab (Sanofi; CD38-directed monoclonal antibody), iberdomide (Bristol Myers Squibb/Celgene;…
NCT07601100 Exploratory - New trial
Colorectal cancer
Phase 2 botensilimab Fc‑enhanced anti‑CTLA‑4 + balstilimab PD‑1 antibody in MSS colon cancer
City of Hope Medical Center is running this Phase 2 neoadjuvant study (NEST3) testing whether short-course dual checkpoint blockade—botensilimab (a next‑generation, Fc‑enhanced anti‑CTLA‑4 monoclonal antibody) plus…
NCT07595874 Exploratory - New trial Spotlight
Lymphoma
Phase 1 CART-45 anti-CD45 CAR T + CD45 base-edited HSPC epitope shield
University of Pennsylvania’s Phase 1 open-label, dose-finding study evaluates a two-step, autologous cell-therapy strategy: infusion of CD45 base-edited hematopoietic stem and progenitor cells (CD45BE-HSPC) followed…
NCT07451054 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1 TCR1188-ABC KRAS G12V TCR + ILT4 (LILRB2)–redirected base-edited T cells
This University of Pennsylvania first-in-human, Phase 1, open-label 3+3 dose-escalation study tests TCR1188-ABC: autologous CD4+ and CD8+ T cells that are base-edited and engineered to (1) express a high-affinity,…
NCT07594067 First-in-human - New trial
Multiple solid tumors
Phase 2 FLOT (docetaxel microtubule inhibitor) consolidation after CRT in localized EAC/EGJ
This Duke University single-arm Phase 2 study tests whether adding consolidative multi-agent chemotherapy after standard upfront chemoradiation can improve disease control and increase organ preservation (avoiding…
NCT07603375 Exploratory - New trial
Multiple solid tumors
Phase 1/1b futibatinib FGFR1–4 inhibitor + paclitaxel + ramucirumab VEGFR2 mAb in 2L gastroesophageal adenocarcinoma.
This Phase 1/1b, open-label dose-escalation/expansion study tests whether adding futibatinib (Lytgobi; an irreversible covalent FGFR1–4 tyrosine kinase inhibitor, from Taiho Oncology/Taiho Pharmaceutical) to the…
NCT07594548 Exploratory - New trial
Multiple solid tumors
Phase 1/2 IDP-001 EGFR×CDCP1 bispecific ADC (proximity-guided co-targeting)
InduPro’s Phase 1/2 open-label, sequential-assignment study evaluates IDP-001 given by IV infusion in two parts: Part 1 dose escalation across advanced/metastatic solid tumors to define safety/tolerability,…
NCT07602842 First-in-human - New trial
Multiple solid tumors
Phase 2 LATTICE radiotherapy spatially fractionated SBRT vs dose-escalated palliative RT.
Stanford University is running an unblinded, randomized Phase 2 study testing whether LATTICE radiotherapy—a spatially fractionated stereotactic technique that delivers a lower “background” dose to the full…
NCT07594431 Exploratory - New trial
Multiple solid tumors
Phase 1b/2 navlimetostat (BMS-986504) PRMT5 inhibitor + pemetrexed antifolate in MTAP-deleted tumors.
This Phase 1b/2 basket study at Northwestern University evaluates navlimetostat (BMS-986504; Bristol Myers Squibb)—an MTA-cooperative PRMT5 inhibitor that exploits the MTAP-deletion synthetic-lethality…
NCT07594626 Exploratory - New trial
Multiple solid tumors
Phase 1 JNJ-1761981 ER intratumoral extended-release cisplatin in solid tumors
This Phase 1 open-label Johnson & Johnson Enterprise Innovation study tests intratumoral JNJ-1761981 ER, an extended-release cisplatin formulation designed to deliver platinum DNA-damaging chemotherapy directly into…
NCT07525141 First-in-human - Trial result
Breast cancer
Carboplatin + nivolumab (PD-1) misses primary PFS endpoint in 1L mTNBC, signal in PD-L1+ (SP142 IC≥1%)
Carboplatin plus nivolumab is a platinum chemotherapy + anti–PD-1 checkpoint inhibitor regimen tested vs carboplatin alone in a randomized Phase II first-line metastatic TNBC trial (NCT03414684). In the mITT…
NCT03414684 - Trial result
Breast cancer
SABR (definitive breast RT) + endocrine therapy hits 53% pCR, enabling surgery omission in low-risk HR+ breast cancer
Definitive stereotactic ablative radiotherapy (SABR; 5 fractions) plus endocrine therapy (ET) was tested as a non-operative strategy in a prospective Phase II trial (NCT02945579) for select patients aged ≥40 with…
NCT02945579 - Trial result Spotlight
Brain and CNS tumors
ML-guided PPRT (dose-escalated RT boost) doubles PFS in newly diagnosed IDH-wt glioblastoma—at a necrosis cost
Personalized precision radiation therapy (PPRT) is an ML-guided radiotherapy dose-escalation approach that uses MRI-derived “tumor infiltration” maps to boost dose beyond conventional fields; it was prospectively…
NCT03477513 - Trial result
Brain and CNS tumors
GNOS-PV01 personalized neoantigen DNA vaccine drives T-cell expansion and ~16.3-mo mOS in MGMT-unmethylated GBM
GNOS-PV01 is a personalized, multivalent neoantigen DNA therapeutic cancer vaccine (up to 40 neoantigens/patient) given adjuvantly after surgical resection and radiotherapy in the open-label, single-arm Phase 1 GT-20…
NCT04015700
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.